Trial
NCT04287894
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
The Netherlands Cancer Institute
Collaborators
AstraZeneca
Condition
Stage III NSCLC
Intervention
Durvalumab
Why stopped
Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-06